For example, quizartinib, a potent selective type 2 FLT3 inhibitor combined with chemotherapy, demonstrated antitumor activity and an acceptable safety profile in patients who are FLT3-ITD-positive and newly diagnosed with AML [35]. Here, FLT3 is linked to acute myeloid leukemia.